Compare PEG & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEG | RMD |
|---|---|---|
| Founded | 1903 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6B | 32.4B |
| IPO Year | 1994 | 1996 |
| Metric | PEG | RMD |
|---|---|---|
| Price | $75.32 | $230.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $92.79 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 2.6M | 1.4M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.37% | 1.13% |
| EPS Growth | ★ 19.21 | 9.67 |
| EPS | 2.15 | ★ 10.43 |
| Revenue | ★ $12,168,000,000.00 | $2,957,013,000.00 |
| Revenue This Year | $4.89 | $10.60 |
| Revenue Next Year | $4.16 | $7.41 |
| P/E Ratio | $35.16 | ★ $21.09 |
| Revenue Growth | ★ 18.25 | 13.44 |
| 52 Week Low | $74.20 | $180.27 |
| 52 Week High | $87.63 | $293.81 |
| Indicator | PEG | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 62.41 |
| Support Level | $74.20 | $199.75 |
| Resistance Level | $81.50 | $233.75 |
| Average True Range (ATR) | 1.26 | 7.21 |
| MACD | 0.05 | 0.34 |
| Stochastic Oscillator | 35.59 | 92.97 |
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plants and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system under a contract extension through 2030. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.